Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review

Current Treatment Options in Oncology
Sakshi Jasra, Jesus Anampa

Abstract

Anthracycline-based regimens have been an important treatment component for patients with breast cancer. As demonstrated in the last Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis, anthracycline-based regimens decrease breast cancer mortality by 20-30%. Anthracycline toxicities include the rare-but potential morbid-cardiotoxicity or leukemogenic effect, and the almost universal-but very distressing-alopecia. Due to potential toxicities, and large number of patients being exposed, several worldwide trials have re-examined the role of anthracycline-based regimens in the management of breast cancer. Current literature supports that anthracyclines are not required for all patients with breast cancer and should be avoided in those with high cardiac risk. Recent results from the ABC trials suggest that anthracyclines should not be spared for patients with triple negative breast cancer (regardless of axillary node involvement) or HER2-/ER+ with significant node involvement. Based on current literature, for HER2-negative patients with low-risk breast cancer, anthracyclines could be spared with regimens such as cyclophosphamide, methotrexate, and fluorouracil (CMF) or docetaxel and cyclophosphamide (TC). Patie...Continue Reading

References

Feb 19, 1976·The New England Journal of Medicine·G BonadonnaU Veronesi
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A GustersonR Reed
Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Pedersen-BjergaardP Dombernowsky
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C AllredL Eudey
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherS Legault-Poisson
Apr 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherJ Wittliff
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ShepherdM Levine
May 5, 1994·The New England Journal of Medicine·W C WoodC R Ferree
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M SwainR A Gams
Sep 24, 1998·The New England Journal of Medicine·P K Singal, N Iliskovic
Dec 21, 2000·American Journal of Physiology. Cell Physiology·D A SiwikW S Colucci
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ZambettiL Gianni
Jan 5, 2001·Redox Report : Communications in Free Radical Research·J C Kwok, D R Richardson
Mar 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K ParkS Han
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Arriagada, J Gutiérrez
Jun 3, 2004·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Carolyn S Massey
Jun 29, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Paul J HeskethDenise Yardley
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudio PragaDavid Rogers
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Oct 28, 2005·The New England Journal of Medicine·Donald A BerryUNKNOWN Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators
May 19, 2006·The New England Journal of Medicine·Kathleen I PritchardUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Feb 20, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Bent EjlertsenJonas Bergh
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary C PinderSharon H Giordano
Aug 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniDouglas B Sawyer
Nov 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martee L HensleyLynn M Schuchter
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JonesMichael A Savin
Jun 16, 2009·Current Oncology·K M KingS Rix
Jul 29, 2009·Psycho-oncology·Corina J G van den HurkWim P M Breed
Jul 1, 2005·Women's Health·Alessandra Balduzzi, Monica Castiglione-Gertsch
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Nov 26, 2010·Journal of the National Cancer Institute·Luisa BonillaSalomon M Stemmer
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael F PressDennis J Slamon
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark

❮ Previous
Next ❯

Citations

Dec 11, 2019·Current Topics in Medicinal Chemistry·Juliana S NovaisFernando de C da Silva
Apr 22, 2020·ChemMedChem·Maristela B Martins-Teixeira, Ivone Carvalho
Sep 24, 2018·Clinical and Experimental Pharmacology & Physiology·Raphaëlle CorremansCarmen Brás-Silva
Dec 1, 2019·Biomolecules·Tala M Abu SamaanDietrich Büsselberg
Sep 14, 2018·International Journal of Molecular Sciences·Alma D Campos-ParraCarlos Pérez-Plasencia
Sep 26, 2020·Journal of Enzyme Inhibition and Medicinal Chemistry·Kamila BuzunAgnieszka Gornowicz
Apr 4, 2021·International Journal of Molecular Sciences·Áron Bartha, Balázs Győrffy
Mar 31, 2021·Clinical Breast Cancer·Reshma MahtaniUNKNOWN Breast Cancer Therapy Expert Group (BCTEG)
Apr 10, 2021·Molecular and Cellular Biochemistry·Sonu S VargheseDavinder S Jassal
May 1, 2021·Journal of Clinical Medicine·Michał BohdanEwa Lewicka
Jun 8, 2021·Cancer Biomarkers : Section a of Disease Markers·Yi ZhangZhigang Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

© 2022 Meta ULC. All rights reserved